Novo Nordisk's pipeline, especially the oral GLP-1 and Alzheimer’s trial, offers significant long-term upside. Click here to ...

One in eight Americans use GLP-1 weight-loss drugs, but are they getting the real thing? Novo Nordisk's dramatic exit from a ...

In the closing of the recent trading day, Novo Nordisk (NVO) stood at $71.01, denoting a +1.89% move from the preceding trading day.

In a recent panel conversation, healthcare and industry experts discussed where to find reliable guidance in a sea of ...

Among them, WW International (WW), formerly known as WeightWatchers, hit a rough patch earlier this year, resulting in WW ...

Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will ...

An updated edition of the June 4, 2025 article. The world is in the midst of a historic demographic shift with populations ...

Hims & Hers will begin offering generic semaglutide drugs in Canada next year after Novo Nordisk lost its exclusive patent ...

Gabapentin, which is used to treat seizures, nerve pain and restless leg syndrome might be linked with increased risk of ...

With thousands of press releases published each month, it can be difficult to keep up with everything on PR Newswire. To help ...

A 200% tariff rate — even with a delay — will have a detrimental effect on drug prices and profit margins, analysts warn.

Ozempic is an FDA-approved medication for people who have type 2 diabetes. It’s often prescribed “off-label” for weight loss ...